provectus biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. provectus’ investigational oncology drug, pv-10, is an ablative immunotherapy under investigation in solid tumor cancers.
Company profile
Ticker
PVCT
Exchange
Website
CEO
Bruce Horowitz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PROVECTUS PHARMACEUTICAL INC, PROVECTUS PHARMACEUTICALS INC, SPM GROUP INC, ZAMAGE DIGITAL IMAGING INC
SEC CIK
Corporate docs
IRS number
900031917
PVCT stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Mar 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
8-K
Regulation FD Disclosure
22 Feb 24
8-K
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
15 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Regulation FD Disclosure
21 Jun 23
DEFA14A
Additional proxy soliciting materials
21 Jun 23
ARS
2022 FY
Annual report to shareholders
11 May 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Sep 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.41 mm | 1.41 mm | 1.41 mm | 1.41 mm | 1.41 mm | 1.41 mm |
Cash burn (monthly) | (no burn) | 25.10 k | 238.05 k | 248.36 k | 256.29 k | 230.46 k |
Cash used (since last report) | n/a | 149.92 k | 1.42 mm | 1.48 mm | 1.53 mm | 1.38 mm |
Cash remaining | n/a | 1.26 mm | -11.88 k | -73.46 k | -120.86 k | 33.44 k |
Runway (months of cash) | n/a | 50.2 | -0.0 | -0.3 | -0.5 | 0.1 |
Institutional ownership, Q2 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 19.11 mm |
Total shares | 168.62 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Home Federal Bank Of Tennessee | 100.00 k | $11.30 mm |
Atlas Wealth | 26.62 k | $3.06 mm |
LBMC Investment Advisors | 22.00 k | $2.49 mm |
Academy Capital Management | 20.00 k | $2.26 mm |
Huntington National Bank | 1.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Grant | Acquire A | No | No | 400000 | - | 400.00 k | - |
21 Mar 24 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Grant | Acquire A | No | No | 25000 | - | 25.00 k | - |
17 Mar 24 | Pershing Edward | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 47,190 | 0.00 | 1,093,762 |
17 Mar 24 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Option exercise | Dispose M | No | No | 2.862 | - | 125.00 k | - |
27 Feb 24 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Grant | Acquire A | No | No | 180000 | - | 180.00 k | - |